Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider
MILAN, Italy and NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power
of hematopoietic stem cells to provide durable and safe treatments for solid tumors, announces that it held its Ordinary and Extraordinary Shareholders' Meeting on May 2, 2024. At the Ordinary and
Extraordinary Shareholders' Meeting, the Company's shareholders approved the appointment of five directors to the Company's Board of Directors, effective as of May 2, 2024, including four new
members. The new members of the Board include: John L. Cantello, Ph.D., Lauren H. Chung, Ph.D., Armon R. Sharei, Ph.D. and Todd Wider, M.D., and Pierluigi
Paracchi, Chief Executive Officer, will continue to serve on the Board as Chairman.
"When Luigi Naldini, Ph.D., M.D., and I co-founded Genenta, we always aspired to involve leading figures in the biotech sector. This Board is fantastic. Our new directors will support Genenta as we aim to consolidate the important results we have achieved so far and to expand the potential impact of our cell therapy for treating tumors," said Pierluigi Paracchi.
The Company extends its thanks to the former members of its Board for their significant contributions throughout their service.
John L. Cantello, Ph.D.
John is an independent advisor to the biopharma industry with over 20 years of experience. John served as the Former VP and Head of Business Development, Oncology Therapy Area at GlaxoSmithKline
and VP and Head of BD, Respiratory & Immune Diseases at AstraZeneca. John has led teams accountable for assessing, valuing, and transacting M&A, pipeline & commercial asset deals
covering oncology, respiratory, inflammation, metabolic, and rare diseases. He has a track record of closing deals (transacting >$30B in deal value) representing primary care, specialty care,
and rare diseases.
Lesen Sie auch
Lauren H. Chung, Ph.D.
Lauren has over 20 years of operating experience spearheading agile investment management strategies and tactical asset allocation in the healthcare industry. As the founder and CEO of Minleigh
LLC, a healthcare focused strategic advisory firm, Lauren has advised leadership, boards, and investment firms on global strategic plans, M&A, integration, and compliance. Previously, Lauren
co-founded Tokum Capital Management, a global institutional healthcare fund, and successfully managed its merger with Perella Weinberg Partners. Lauren serves on public and private company boards.
She has a Ph.D. in Biomedical Sciences from Columbia University Vagelos College of Physicians and Surgeons, an M.B.A. from Columbia Business School, and a B.A. in Biochemistry and Economics with
Honors from Wellesley College.